Filtered By:
Drug: Prozac

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 193 results found since Jan 2013.

More Doctors Are Prescribing Exercise Instead Of Medication
BOSTON (AP) — When Dr. Michelle Johnson scribbles out prescriptions, the next stop for many of her patients is the gym, not the pharmacy. Doctors treating chronic health problems increasingly are prescribing exercise for their patients — and encouraging them to think of physical activity as their new medication. In one such program run by a health center in Boston’s Roxbury neighborhood, primary care physicians, internists and psychologists prescribe access to a gym for $10 a month, including free child care, classes and kids programs. Providing affordable gym access for patients ensures compliance, said Gibbs Sa...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 15, 2016 Category: Consumer Health News Authors: deanreddington Tags: Health Local News Exercise Ken MacLeod Source Type: news

Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53.
Abstract Fluoxetine, a selective serotonin reuptake inhibitor, exerts neuroprotective effects in a variety of neurological diseases including stroke, but the underlying mechanism remains obscure. In the present study, we addressed the molecular events in fluoxetine against ischemia/reperfusion-induced acute neuronal injury and inflammation-induced neuronal apoptosis. We showed that treatment of fluoxetine (40 mg/kg, i.p.) with twice injections at 1 h and 12 h after transient middle cerebral artery occlusion (tMCAO) respectively alleviated neurological deficits and neuronal apoptosis in a mouse ischemic stroke mode...
Source: Neuropharmacology - March 11, 2016 Category: Drugs & Pharmacology Authors: Shan H, Bian Y, Shu Z, Zhang L, Zhu J, Ding J, Lu M, Xiao M, Hu G Tags: Neuropharmacology Source Type: research

Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke.
CONCLUSIONS: In patients with ischemic stroke, early administration of fluoxetine may improve the neurological functional prognosis. PMID: 26923613 [PubMed - as supplied by publisher]
Source: Restorative Neurology and Neuroscience - March 1, 2016 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China
We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 25, 2016 Category: Neurology Authors: Yi-Tao He, Bing-Shan Tang, Zhi-Li Cai, Si-Ling Zeng, Xin Jiang, Yi Guo Source Type: research

Should This Patient With Ischemic Stroke Receive Fluoxetine?
Publication date: December 2015 Source:PM&R, Volume 7, Issue 12 Author(s): Heidi Schambra, Brian Im, Michael W. O'Dell
Source: PMandR - December 18, 2015 Category: Rehabilitation Source Type: research

Holistic Solutions for Anxiety & Depression in Therapy
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.” — Hippocrates (460-377 B.C.E.) “The art of healing comes from nature and not from the physician. Therefore, the physician must start from nature with an open mind.” — Paracelsus (1493 – 1541) Treatment options that have long been considered outside the mainstream are becoming commonplace: a survey shows that nearly two in five adults in the United States have tried complementary or alternative therapy in the last year. As clinicians, it is our job to work with the individual t...
Source: Psych Central - December 8, 2015 Category: Psychiatry Authors: Megan Riddle Tags: Anxiety Book Reviews Depression General Happiness Herbs & Supplements Medications Professional Self-Help Stress Treatment anxiety treatment combining natural remedies with conventional care Depression Treatment holistic solutio Source Type: news

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Should This Patient With Ischemic Stroke Receive Fluoxetine?
You admit T.R., a 75-year-old man, to your inpatient rehabilitation unit 10 days after a stroke. He has a medical history of hypertension and type II diabetes. On the day of his admission to the neurology service, he experienced a sudden onset of severe left-sided weakness with a facial droop and slurring of speech. His husband was driving them both to a social event at the time and detoured immediately to the emergency department, where the patient received tissue plasminogen activator (tPA) for a large, right middle cerebral artery thrombosis seen on magnetic resonance imaging.
Source: PM and R - December 1, 2015 Category: Rehabilitation Authors: Heidi Schambra, Brian Im, Michael W. O'Dell Tags: Point/Counterpoint Source Type: research

Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine.
Abstract Ceramides induce important intracellular signaling pathways, modulating proliferation, migration, apoptosis, and inflammation. However, the relevance of the ceramide metabolism in the reconvalescence phase after stroke is unclear. Besides its well-known property as a selective serotonin reuptake inhibitor, fluoxetine has been reported to inhibit the acid sphingomyelinase (ASM), a key regulator of ceramide levels which derives ceramide from sphingomyelin. Furthermore, fluoxetine has shown therapeutic potential in a randomized controlled rehabilitation trial in stroke patients. Our aim was to investigate an...
Source: Neural Plasticity - November 27, 2015 Category: Neurology Authors: Brunkhorst R, Friedlaender F, Ferreirós N, Schwalm S, Koch A, Grammatikos G, Toennes S, Foerch C, Pfeilschifter J, Pfeilschifter W Tags: Neural Plast Source Type: research

Fluoxetine Enhances Neurogenesis in Aged Rats with Cortical Infarcts, but This is not Reflected in a Behavioral Recovery
Abstract Age is associated with poor outcome and impaired functional recovery after stroke. Fluoxetine, which is widely used in clinical practice, can regulate hippocampal neurogenesis in young rodents. As the rate of neurogenesis is dramatically reduced during aging, we studied the effect of post-stroke fluoxetine treatment on neurogenesis in the subventricular zone (SVZ) and subgranular zone (SGZ) of dentate gyrus (DG) and whether this would be associated with any behavioral recovery after the cortical infarct in aged rats. Aged rats were randomly assigned to four groups: sham-operated rats, sham-operated rats t...
Source: Journal of Molecular Neuroscience - October 16, 2015 Category: Neuroscience Source Type: research

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report
Conclusion Given emerging evidence that mitochondrial dysfunction, particularly in the electron transport chain needed for cellular energy production, is an underlying pathophysiological mechanism for some varieties of ASD, clinicians should have a high index of suspicion for mitochondrial disease, especially when they encounter a patient with unusual neurological or constitutional symptoms. The prevalence of mitochondrial disease in ASD patients may be as high as five percent, which means that it is not the “zebra”[27] diagnosis that it might be in a non-ASD patient, where prevalence is about 0.01 percent.10 Reference...
Source: Innovations in Clinical Neuroscience - October 9, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Asperger's syndrome Autism Behavioral and Cognitive Neurology Case Report Current Issue Intellectual Disability Neurologic Systems and Symptoms Pervasive Developmental Disorders ASD autism spectrum disorder dysauton Source Type: research

So you think you can jump? A novel long jump assessment to detect deficits in stroked mice
Conclusions This study introduces a novel assay that can be used to measure a stroke induced behavioral deficit with great sensitivity, and raises interesting questions about potential mechanisms regulating this effect.
Source: Journal of Neuroscience Methods - September 29, 2015 Category: Neuroscience Source Type: research

Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model Basic Sciences
Conclusions— There is a gradient of diminishing responsiveness to motor training over the first week after stroke. Fluoxetine can overcome this gradient and maintain maximal levels of responsiveness to training even 7 days after stroke.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Ng, K. L., Gibson, E. M., Hubbard, R., Yang, J., Caffo, B., O'Brien, R. J., Krakauer, J. W., Zeiler, S. R. Tags: Animal models of human disease, Behavioral Changes and Stroke, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Comparison between herbal medicine and fluoxetine for depression: A systematic review of randomized controlled trials.
CONCLUSIONS: Due to the poor quality of included trials and the potential publication bias of this review, no confirmed conclusion could be draw to evaluate the effectiveness and safety of CHM for depression compared with fluoxetine. PMID: 26365447 [PubMed - in process]
Source: Complementary Therapies in Medicine - September 16, 2015 Category: Complementary Medicine Authors: Ren Y, Zhu C, Wu J, Zheng R, Cao H Tags: Complement Ther Med Source Type: research